
Henry Schein (HSIC) Stock Forecast & Price Target
Henry Schein (HSIC) Analyst Ratings
Bulls say
Henry Schein Inc. has demonstrated solid revenue growth across its key segments, with medical products revenue increasing by 4.7% as reported and 3.0% on a local internal basis, accompanied by noticeable growth in the dental sector, where revenue rose by 5.5% on both reported and local internal metrics. Additionally, the global technology segment showed significant performance, generating $173 million in revenue and growing by 9.7% as reported, indicating a strong demand for technology solutions within the healthcare space. The company anticipates adjusted EBITDA to grow in the mid-single digits for 2025 compared to FY/24, reflecting ongoing operational resilience and strategic value creation.
Bears say
Henry Schein Inc. reported gross margins that consistently fell short of expectations, with figures of 30.9% and 30.7% for the recent quarters, indicating challenges in maintaining profitability. Additionally, the company anticipates lower remeasurement gains in 2026 compared to 2025, which poses potential risks to future earnings, exacerbated by an unfavorable product mix in its distribution and specialty products segments. Although M&A and foreign currency effects provided modest tailwinds, these factors may not be sufficient to offset the underlying operational difficulties contributing to the negative outlook on the company’s stock.
This aggregate rating is based on analysts' research of Henry Schein and is not a guaranteed prediction by Public.com or investment advice.
Henry Schein (HSIC) Analyst Forecast & Price Prediction
Start investing in Henry Schein (HSIC)
Order type
Buy in
Order amount
Est. shares
0 shares